Cantor Fitzgerald analyst Charles Duncan lowered the firm’s price target on Lucid Diagnostics to $3 from $3.80 and keeps an Overweight rating on the shares. The firm views Lucid’s EsoGuard/EsoCheck offerings favorably in light of their potential to become the new first-line screen for Barrett’s esophagus-esophageal adenocarcinoma in the conservatively estimated $25B U.S. market, and views the company’s stock as materially undervalued, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
- Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
- Lucid Diagnostics reports preliminary Q4 adjusted EPS (23c), consensus (26c)
- LUCD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Lucid Diagnostics announces data from clinical validation study of EsoGuardPAVmed